GARY A LYONS Insider Trading $NBIX NEUROCRINE BIOSCIENCES INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GARY A LYONS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GARY A LYONS. GARY A LYONS is in Brickell Biotech, Inc. ($VICL) and Director in VICAL INC ($VICL) and Director in NEUROCRINE BIOSCIENCES INC ($NBIX) and Director in Ardea Biosciences, Inc./DE ($IBPI) and Director in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in CYTORI THERAPEUTICS, INC. ($XMP) and Director in KALOBIOS PHARMACEUTICALS INC ($KBIO) and Director in Novus Therapeutics, Inc. ($TKAI) and Director in Retrophin, Inc. ($RTRX).
GARY A LYONS in NEUROCRINE BIOSCIENCES INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of GARY A LYONS: Director
Holdings: 224,097 shares
Current Value: $9,770,629
Latest Transaction: Jan 27 2021
$NBIX Market Capitalization: $3.81B
$NBIX Previous Close: $43.60
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of GARY A LYONS in NEUROCRINE BIOSCIENCES INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, IBPI, VICL, ELDN, KBIO, NBIX, PSTV, RIGL, RTRX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.00 | 400 | 48,000 | 223,697 | 224.1 K to 223.7 K (-0.18 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 120.03 | 1,600 | 192,047 | 224,097 | 225.7 K to 224.1 K (-0.71 %) |
| May 21 2020 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 119.93 | 6,018 | 721,739 | 6,018 | |
| Nov 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 110.00 | 5,000 | 550,000 | 225,697 | 230.7 K to 225.7 K (-2.17 %) |
| Nov 05 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 100.22 | 5,000 | 501,104 | 230,697 | 235.7 K to 230.7 K (-2.12 %) |
| Jul 31 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 92.07 | 10,000 | 920,686 | 235,697 | 245.7 K to 235.7 K (-4.07 %) |
| May 23 2019 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 79.79 | 10,000 | 797,900 | 10,000 | |
| Nov 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 114.41 | 15,000 | 1,716,213 | 245,697 | 260.7 K to 245.7 K (-5.75 %) |
| Jun 15 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 99.24 | 15,000 | 1,488,549 | 260,697 | 275.7 K to 260.7 K (-5.44 %) |
| May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
| May 25 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 94.64 | 12,500 | 1,183,000 | 12,500 | |
| Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 7.05 | 15,000 | 105,750 | 0 | |
| Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Payment of Exercise | F | 77.23 | 1,369 | 105,728 | 275,697 | 277.1 K to 275.7 K (-0.49 %) |
| Apr 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 7.05 | 15,000 | 105,750 | 277,066 | 262.1 K to 277.1 K (+5.72 %) |
| Feb 20 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 84.67 | 5,000 | 423,341 | 262,066 | 267.1 K to 262.1 K (-1.87 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 83.08 | 5,000 | 415,380 | 267,066 | 272.1 K to 267.1 K (-1.84 %) |
| Dec 05 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 72.92 | 10,000 | 729,182 | 272,066 | 282.1 K to 272.1 K (-3.55 %) |
| Jun 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 53.64 | 15,000 | 804,600 | 15,000 | |
| Feb 15 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 3.40 | 15,000 | 51,000 | 0 | |
| Feb 15 2017 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 3.40 | 15,000 | 51,000 | 282,066 | 267.1 K to 282.1 K (+5.62 %) |
| May 24 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 47.89 | 15,000 | 718,350 | 15,000 | |
| May 10 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | M | 3.07 | 15,000 | 46,050 | 0 | |
| May 10 2016 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Buy | M | 3.07 | 15,000 | 46,050 | 267,066 | 252.1 K to 267.1 K (+5.95 %) |
| Sep 21 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 54.66 | 5,000 | 273,300 | 252,066 | 257.1 K to 252.1 K (-1.95 %) |
| Sep 21 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 55.00 | 10,000 | 550,000 | 257,066 | 267.1 K to 257.1 K (-3.74 %) |
| Jun 01 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Option Exercise | A | 42.76 | 25,000 | 1,069,000 | 25,000 | |
| Mar 24 2015 | NBIX | NEUROCRINE BIOSCIE ... | LYONS GARY A | Director | Sell | S | 41.53 | 30,000 | 1,245,900 | 267,066 | 297.1 K to 267.1 K (-10.10 %) |
Page: 1